Literature DB >> 18456719

Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders.

A-M Nyström1, S Ekvall, E Berglund, M Björkqvist, G Braathen, K Duchen, H Enell, E Holmberg, U Holmlund, M Olsson-Engman, G Annerén, M-L Bondeson.   

Abstract

BACKGROUND: Noonan syndrome (NS) and cardio-facio-cutaneous syndrome (CFC) are related disorders associated with disrupted RAS/RAF/MEK/ERK signalling. NS, characterised by facial dysmorphism, congenital heart defects and short stature, is caused by mutations in the genes PTPN11, SOS1, KRAS and RAF1. CFC is distinguished from NS by the presence of ectodermal abnormalities and more severe mental retardation in addition to the NS phenotype. The genetic aetiology of CFC was recently assigned to four genes: BRAF, KRAS, MEK1 and MEK2.
METHODS: A comprehensive mutation analysis of BRAF, KRAS, MEK1, MEK2 and SOS1 in 31 unrelated patients without mutations in PTPN11 is presented.
RESULTS: Mutations were identified in seven patients with CFC (two in BRAF, one in KRAS, one in MEK1, two in MEK2 and one in SOS1). Two mutations were novel: MEK1 E203Q and MEK2 F57L. The SOS1 E433K mutation, identified in a patient diagnosed with CFC, has previously been reported in patients with NS. In one patient with NS, we also identified a mutation, BRAF K499E, that has previously been reported in patients with CFC. We thus suggest involvement of BRAF in the pathogenesis of NS also.
CONCLUSIONS: Taken together, our results indicate that the molecular and clinical overlap between CFC and NS is more complex than previously suggested and that the syndromes might even represent allelic disorders. Furthermore, we suggest that the diagnosis should be refined to, for example, NS-PTPN11-associated or CFC-BRAF-associated syndromes after the genetic defect has been established, as this may affect the prognosis and treatment of the patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18456719     DOI: 10.1136/jmg.2008.057653

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  31 in total

1.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

2.  Cardio-facio-cutaneous syndrome: does genotype predict phenotype?

Authors:  Judith E Allanson; Göran Annerén; Yoki Aoki; Christine M Armour; Marie-Louise Bondeson; Helene Cave; Karen W Gripp; Bronwyn Kerr; Anna-Maja Nystrom; Katia Sol-Church; Alain Verloes; Martin Zenker
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-04-14       Impact factor: 3.908

3.  Epicardial control of myocardial proliferation and morphogenesis.

Authors:  Henry M Sucov; Ying Gu; Simmy Thomas; Peng Li; Mohammad Pashmforoush
Journal:  Pediatr Cardiol       Date:  2009-03-10       Impact factor: 1.655

4.  In vivo severity ranking of Ras pathway mutations associated with developmental disorders.

Authors:  Granton A Jindal; Yogesh Goyal; Kei Yamaya; Alan S Futran; Iason Kountouridis; Courtney A Balgobin; Trudi Schüpbach; Rebecca D Burdine; Stanislav Y Shvartsman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-03       Impact factor: 11.205

5.  Comprehensive massive parallel DNA sequencing strategy for the genetic diagnosis of the neuro-cardio-facio-cutaneous syndromes.

Authors:  Ana Justino; Patrícia Dias; Maria João Pina; Sónia Sousa; Luís Cirnes; Ana Berta Sousa; José Carlos Machado; José Luis Costa
Journal:  Eur J Hum Genet       Date:  2014-06-04       Impact factor: 4.246

6.  Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer.

Authors:  Aphrothiti J Hanrahan; Brooke E Sylvester; Matthew T Chang; Arijh Elzein; Jianjiong Gao; Weiwei Han; Ye Liu; Dong Xu; Sizhi P Gao; Alexander N Gorelick; Alexis M Jones; Amber J Kiliti; Moriah H Nissan; Clare A Nimura; Abigail N Poteshman; Zhan Yao; Yijun Gao; Wenhuo Hu; Hannah C Wise; Elena I Gavrila; Alexander N Shoushtari; Shakuntala Tiwari; Agnes Viale; Omar Abdel-Wahab; Taha Merghoub; Michael F Berger; Neal Rosen; Barry S Taylor; David B Solit
Journal:  Cancer Res       Date:  2020-07-08       Impact factor: 12.701

7.  Assessing the gene-disease association of 19 genes with the RASopathies using the ClinGen gene curation framework.

Authors:  Andrew R Grant; Brandon J Cushman; Hélène Cavé; Mitchell W Dillon; Bruce D Gelb; Karen W Gripp; Jennifer A Lee; Heather Mason-Suares; Katherine A Rauen; Marco Tartaglia; Lisa M Vincent; Martin Zenker
Journal:  Hum Mutat       Date:  2018-11       Impact factor: 4.878

8.  The language phenotype of children and adolescents with Noonan syndrome.

Authors:  Elizabeth I Pierpont; Susan Ellis Weismer; Amy E Roberts; Erica Tworog-Dube; Mary Ella Pierpont; Nancy J Mendelsohn; Mark S Seidenberg
Journal:  J Speech Lang Hear Res       Date:  2010-06-11       Impact factor: 2.297

9.  Noonan syndrome: comparing mutation-positive with mutation-negative dutch patients.

Authors:  E A Croonen; W Nillesen; C Schrander; M Jongmans; H Scheffer; C Noordam; J M T Draaisma; I van der Burgt; H G Yntema
Journal:  Mol Syndromol       Date:  2013-05-08

10.  Genotype differences in cognitive functioning in Noonan syndrome.

Authors:  E I Pierpont; M E Pierpont; N J Mendelsohn; A E Roberts; E Tworog-Dube; M S Seidenberg
Journal:  Genes Brain Behav       Date:  2008-12-11       Impact factor: 3.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.